Please ensure Javascript is enabled for purposes of website accessibility

Regenerative Tissue Developer Humacyte Going Public Via SPAC

By Taylor Carmichael - Updated Feb 18, 2021 at 1:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.

Alpha Healthcare Acquisition (AHAC), a special purpose acquisition company (SPAC), is being acquired by privately held Humacyte in a reverse-merger. Humacyte is a world leader in the field of regenerative medicine. The deal is expected to close in the second quarter; the new company will trade on the NASDAQ under the ticker "HUMA."

Alpha Healthcare Acquisition CEO Rajiv Shukla previously ran Constellation Alpha Capital, the SPAC  that took DermTech public in 2019. Over the last year, shares of DermTech have run up 444%. For his new SPAC, Shukla investigated 95 companies before finally settling on Humacyte, according to an article in Fierce Biotech. It was "by far the best option," he said.

Doctor holding hand under virtual graph art with the words "Regenerative Medicine"

image source: Getty Images

Founded by Laura Niklason in 2004, Humacyte has a platform that takes tissue from donors' circulatory systems and uses it to grow human acellular vessels (HAV). These will be off-the-shelf, universally available, and immediately implantable. Humacyte has finished five phase 3 trials and has three phase 3 trials ongoing. The company's HAV technology has a multitude of real-world applications in vascular trauma, hemodialysis, peripheral arterial disease, diabetes, and coronary artery bypass grafts. Humacyte estimates potential peak sales from its pipeline products of $12 billion a year, assuming approval by the FDA.   

The company will receive $100 million from the deal, plus $175 million raised in a private round of financing. The deal is expected to close in the second quarter, valuing the new company at an estimated $1.1 billion. As of 1:40 p.m. EST Wednesday, Alpha Healthcare Acquisition was up 12.7% on the news of the planned merger. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alpha Healthcare Acquisition Corp. Stock Quote
Alpha Healthcare Acquisition Corp.
Dermira, Inc. Stock Quote
Dermira, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.